EA200200846A1 - Соединения, полезные для лечения или предупреждения заболеваний, опосредуемых альфа-2в-адреноцептором - Google Patents

Соединения, полезные для лечения или предупреждения заболеваний, опосредуемых альфа-2в-адреноцептором

Info

Publication number
EA200200846A1
EA200200846A1 EA200200846A EA200200846A EA200200846A1 EA 200200846 A1 EA200200846 A1 EA 200200846A1 EA 200200846 A EA200200846 A EA 200200846A EA 200200846 A EA200200846 A EA 200200846A EA 200200846 A1 EA200200846 A1 EA 200200846A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alpha
adrenoceptor
prevention
treatment
diseases mediated
Prior art date
Application number
EA200200846A
Other languages
English (en)
Inventor
Зигфрид Вурстер
Миа Энгстрем
Лииса Хуовинен
Сари Каллиокоски
Лейла Келанне
Эва-Лииса Савола
Original Assignee
Ой Ювантиа Фарма Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20000303A external-priority patent/FI20000303A0/fi
Application filed by Ой Ювантиа Фарма Лтд. filed Critical Ой Ювантиа Фарма Лтд.
Publication of EA200200846A1 publication Critical patent/EA200200846A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Настоящее изобретение относится к применению селективного антагониста альфа-2В-адреноцептора для получения фармацевтического препарата, полезного для лечения или предупреждения у млекопитающих заболеваний, опосредуемых альфа-2В-адреноцептором, который является соединением, выбранным из группы, включающей соединения А, В, С, D и Е, раскрытые на схеме 1, или фармацевтически приемлемой солью указанного соединения. Настоящее изобретение также относится к способу лечения или предупреждения заболеваний, опосредуемых альфа-2В-адреноцептором у млекопитающих, который включает введение названному млекопитающему эффективного количества селективного антагониста альфа-2В-адреноцептора.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200846A 2000-02-11 2001-02-07 Соединения, полезные для лечения или предупреждения заболеваний, опосредуемых альфа-2в-адреноцептором EA200200846A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18202100P 2000-02-11 2000-02-11
FI20000303A FI20000303A0 (fi) 2000-02-14 2000-02-14 Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
PCT/FI2001/000105 WO2001058454A1 (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor

Publications (1)

Publication Number Publication Date
EA200200846A1 true EA200200846A1 (ru) 2002-12-26

Family

ID=26160944

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200846A EA200200846A1 (ru) 2000-02-11 2001-02-07 Соединения, полезные для лечения или предупреждения заболеваний, опосредуемых альфа-2в-адреноцептором

Country Status (22)

Country Link
EP (1) EP1253926A1 (ru)
JP (1) JP2003522148A (ru)
KR (1) KR20020080413A (ru)
AU (1) AU780802B2 (ru)
BR (1) BR0108221A (ru)
CA (1) CA2399421A1 (ru)
CZ (1) CZ20022884A3 (ru)
EA (1) EA200200846A1 (ru)
EE (1) EE200200435A (ru)
GE (1) GEP20043356B (ru)
HR (1) HRP20020746A2 (ru)
HU (1) HUP0300032A3 (ru)
IL (1) IL151017A0 (ru)
IS (1) IS6476A (ru)
MX (1) MXPA02007454A (ru)
MY (1) MY133957A (ru)
NO (1) NO20023773L (ru)
NZ (1) NZ520500A (ru)
PL (1) PL357872A1 (ru)
SK (1) SK11472002A3 (ru)
WO (1) WO2001058454A1 (ru)
YU (1) YU59102A (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000615A (es) * 2001-07-20 2004-04-20 Juvantia Pharma Ltd Oy Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor.
FI116940B (fi) 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416432D0 (en) * 1984-06-28 1984-08-01 Wyeth John & Brother Ltd Benzoquinolizines
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US6150389A (en) * 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents

Also Published As

Publication number Publication date
KR20020080413A (ko) 2002-10-23
HUP0300032A3 (en) 2006-01-30
PL357872A1 (en) 2004-07-26
MXPA02007454A (es) 2004-08-23
NZ520500A (en) 2005-01-28
CZ20022884A3 (cs) 2003-02-12
YU59102A (sh) 2005-11-28
WO2001058454A1 (en) 2001-08-16
MY133957A (en) 2007-11-30
JP2003522148A (ja) 2003-07-22
AU3551001A (en) 2001-08-20
BR0108221A (pt) 2003-03-05
AU780802B2 (en) 2005-04-21
NO20023773D0 (no) 2002-08-09
EP1253926A1 (en) 2002-11-06
CA2399421A1 (en) 2001-08-16
HRP20020746A2 (en) 2004-12-31
IL151017A0 (en) 2003-02-12
IS6476A (is) 2002-07-19
NO20023773L (no) 2002-08-09
EE200200435A (et) 2003-12-15
GEP20043356B (en) 2004-04-13
SK11472002A3 (sk) 2003-02-04
HUP0300032A2 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
HK1069339A1 (en) Substituted diketopiperazines as oxytocin antagonists
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
BG66085B1 (bg) Фенилаланинови производни
WO2003048164A3 (en) Adenosine a2a receptor antagonists
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
EA200200846A1 (ru) Соединения, полезные для лечения или предупреждения заболеваний, опосредуемых альфа-2в-адреноцептором
ATE302011T1 (de) PONAZURIL ZUR BEHANDLUNG VON DURCH COCCIDIA NEUROLOGISCHEN UND ßABORTIGENICß VERURSACHTEN ERKRANKUNGEN
RU2001118219A (ru) Ингибитор ангиогенеза
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
DE60004996D1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
BR0214293A (pt) Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmo
DE60115237D1 (de) Praziquantel zusammensetzungen zur behandlung von krankheiten verursacht durch kokzidien
LV12459A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
DE60108775D1 (de) Methode zur behandlung von schlaganfall
MX9605153A (es) Agentes farmaceuticos para el tratamiento de enfermedades inflamatorias cronicas y agudas.